Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X about a recent article by Johanna Braegelmann et al. published in Journal of Neuroendocrinology:
“Somatostatin analogs for high G2 (Ki-67 10-20%) and G3 NETs, worth trying or not? According to this retrospective study, the PFS in patients with high G2 NETs was 19 months vs. 6 months in G3. Patients with a higher liver tumor burden defined as >10% of liver volume had a shorter PFS but the number of patients was low.
Take home message: SSAs are reasonable as initial therapy in high G2 and G3 NETs assuming follow up is close and patients are offered more effective therapy such as PRRT upon progression.”
Title: Somatostatin analogs in neuroendocrine tumors with Ki-67 index of ≥10%
Authors: Johanna Braegelmann, Annie Mathew, Boerge Schmidt, Hamza Kalisch, Wolfgang P. Fendler, Dagmar Führer-Sakel, Harald Lahner
Read the Full Article on Journal of Neuroendocrinology
More posts featuring Thor Halfdanarson.